FABRICATION OF A NANOCARRIER SYSTEM CONTAINING PLASMA PROTEIN BY OPTIMIZATION USING RESPONSE SURFACE METHODOLOGY
Keywords:
Human serum albumin (HSA), Particle size, yield, pH and optimizationAbstract
Objective: the present investigation involves formulation, optimization and in vitro characterization of size controlled HSA nanoparticles with reproducible process yield.
Methods: Human serum Albumin (HSA) is material of choice for development of depot particulate formulations due to its biodegradable nature and is also considered as the ‘green' eco-friendly material due its biocompatibility and non-toxic properties. HSA nanoparticles, prepared using desolvation technique, have proved to be promising carrier systems for drug delivery to treat brain disorders. The aim of current Owing to the batch-to-batch variability of HSA based carrier systems, the nanoparticles was optimized using response surface methodology supported by statistical tools for designing a robust formulation. Prior to optimization technique, preliminary screening studies were conducted to evaluate the influence of different formulation variables on particle size and percentage process yield of nanoparticles. The critical process variables were further screened using on 32 factorial design for simultaneous optimization of the process parameters by evaluating their impact on quality attributes of nanoparticles.
Results: The nanoparticles were designed and optimized to achieve a mean particle diameter of 144.55±2.2 nm with process yield of 86.13±1.9 % (n=3), respectively. The relationship between the factors and their coefficients was determined mathematically with their respective p-values by employing regression analysis and the factors obtaining p-values<0.05 were considered as significant.
Conclusion: The present studies suggest that the physicochemical properties of HSA can be better exploited as a drug carrier for numerous therapeutic and medical applications.
Â
Downloads
References
Jong DWH, Borm PJ. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomed Jun 2008;3(2):133-49.
Cho K, Wang X, Nie S, Chen Z, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14(5):1310-16.
Mudshingea SR, Deoreb AB, Patil S, Bhalgat CM. Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm J 2011;19(3):129-41.
Xia Y, Sun T, Zhang YS, Pang B, Hyun DC, Yang M. Engineered nanoparticles for drug delivery in cancer therapy. Angew ChemInt 2014;53:12320-64.
Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Amer J Resp Crit Care Med 2005;172:1487-90.
Wang W, Huang Y, Zhao S, Shao T, Cheng Y. Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds. Royal Soc Chem 2013:S1-S16.
Wang W, Huang Y, Zhao S, Shao T, Cheng Y. Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds. Chem Commun 2013;49:2234-6.
Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Satyaprakash. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitroanalysis. Int J Nanomed 2010;5:525-32.
Muro, Das KS, Raizer JJ. Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas. Techn Cancer Res Treat 2006;5(3):201-13.
Smith QR. Carrier-mediated transport to enhance drug delivery to brain. Int Cong Ser 2005;1277:63-74.
Ronaldson PT, Covarrubias LS, Slosky LM, Thompson BJ, Davis TP. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des 2014;20(10):1422-49.
Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 2013;7:27-34.
Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol 2010;596:467-88.
Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm 1999;187:143-52.
Arzaluza NMG, Segundob PE, Ronderoa GA, Ballesterosc LD. Single emulsion-solvent evaporation technique and modifications for the preparation of pharmaceutical polymeric nanoparticles. Recent Pat Drug Delivery Formulation 2012;6:209-23.
Azarmia S, Huanga Y, Chend H, McQuarriea S, Abramse D, Roa W. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharm Sci 2006;9(1):124-32.
Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999;25(4):471-6.
Marty JJ, Oppenheimer RC, Speiser P. Nanoparticles-a new colloidal drug delivery system. Pharm Acta Helv 1978;53:17-23.
Langer K, Balthasar S, Vogel V, Dinauer N, Briesen HV, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003;257:169-80.
Santos KC, Silva DMF, Filho ER, Fernandes JB, Polikarpov I. Polymeric nanoparticles loaded with the 3,5,3′-triiodothyroacetic acid (Triac), a thyroid hormone: factorial design, characterization, and release kinetics. Nanotech Sci App 2012;5:37-48.
Gambhire MS, Bhalekar MR, Gambhire VM. Statistical optimization of dithranol-loaded solid lipid nanoparticles using factorial design. Braz J Pharm Sci 2011;47(3):503-11.
Jain A, Jain SK. Formulation and optimization of temozolomide nanoparticles by 3 factor 2 level factorial design. Biomatter 2013;3(2):e25102-13.
Zu Y, Zhao Q, Zhao X, Zu S, Meng L. Process optimization for the preparation of oligomycin-loaded folate-conjugated chitosan nanoparticles as a tumor-targeted drug delivery system using a two-level factorial design method. Int J Nanomed 2011;6:3429-41.
Murtaza G, Ahmad M, Khan SA. Evaluation of cefixime-loaded chitosan microspheres: Analysis of dissolution data using DDSolver. DissInd 2012:13-9.
Lin W, Coombes GA, Davies MC, Davis SS, Illum L. Preparation of sub-100 nm human serum albumin nanoparticles using a pH-coacervation method. J Drug Target 1993;1:237-43.
Wang G, Siggers K, Zhang S, Jiang H, Xu Z, Zernicke RF. Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 2008;25(12):2896-909.
Namasivayam SK, Robin G. Preparation, optimization and characterization of biocompatible nanoalbumin-ofloxacin (bsanp-of) conjugate and evaluation of control release, anti-bacterial activity against clinical isolate of pseudomonas aeruginosa. Asian J Pharm Clin Res 2013;6(3):235-9.
Shivhare M, McCreath G. Practical Considerations for DoE Implementation in Quality by Design. Bio Process Int 2010:22-30.